Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM230治疗库欣氏病或肢端肥大症伴高血糖患者的疗效评价
CTR20150483Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of pasireotide LAR in Corticotropin adenoma (ACTHoma), acromegaly, hyperglycemia, type 2 diabetes mellitus (T2DM), sponsored by Novartis. Started Sep 2015; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)acromegalyhyperglycemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20150483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150483.